

# JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 70, ISSUE 4, PAGES 583–818

## FROM THE EDITOR'S DESK

### From the Editor's desk. . .

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 583

## EDITORIALS

No safe level of alcohol consumption – Implications for global health

G. Mehta and N. Sheron 587

Hepatic encephalopathy and traffic accidents: Vigilance is needed!

E.B. Tapper, M. Romero-Gómez and J.S. Bajaj 590

## RESEARCH ARTICLES

### Viral Hepatitis

Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants

T. Khera, P. Behrendt, D. Bankwitz, R.J.P. Brown, D. Todt, M. Doepke, A.G. Khan, K. Schulze, J. Law, M. Logan, D. Hockman, J.A.J.-X. Wong, L. Dold, V. Gonzalez-Motos, U. Spengler, A. Viejo-Borbolla, L.J. Ströhl, T. Krey, A.W. Tarr, E. Steinmann, M.P. Manns, F. Klein, C.A. Guzman, J. Marcotrigiano, M. Houghton and T. Pietschmann 593

SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations

R. Costa, D. Todt, F. Zapatero-Belinchón, C. Schenk, O.E. Anastasiou, A. Walker, B. Hertel, L. Timmer, D. Bojkova, M. Ruckert, C. Sarrazin, J. Timm, V. Lohmann, M.P. Manns, E. Steinmann, T. von Hahn and S. Ciesek 603

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients

B. Testoni, F. Lebossé, C. Scholtes, F. Berby, C. Miaglia, M. Subic, A. Loglio, F. Facchetti, P. Lampertico, M. Levrero and F. Zoulim 615

A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu

S. Denolly, C. Granier, N. Fontaine, B. Pozzetto, T. Bourlet, M. Guérin and F.-L. Cosset 626

### Cirrhosis

Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA

R. Hernaez, J.R. Kramer, Y. Liu, A. Tansel, Y. Natarajan, K.B. Hussain, P. Ginès, E. Solà, R. Moreau, A. Gerbes, H.B. El-Serag and F. Kanwal 639

The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability

C. Formentin, M. De Rui, M. Zoncapè, S. Ceccato, L. Zarantonello, M. Senzolo, P. Burra, P. Angeli, P. Amodio and S. Montagnese 648

### Transplantation

Normothermic regional perfusion vs. super-rapid recovery in controlled donation after circulatory death liver transplantation

A.J. Hessheimer, E. Coll, F. Torres, P. Ruíz, M. Gastaca, J.I. Rivas, M. Gómez, B. Sánchez, J. Santoyo, P. Ramírez, P. Parrilla, L.M. Marín, M.Á. Gómez-Bravo, J.C. García-Valdecasas, J. López-Monclús, A. Boscá, R. López-Andújar, J. Fundora-Suárez, J. Villar, Á. García-Sesma, C. Jiménez, G. Rodríguez-Laíz, L. Lladó, J.C. Rodríguez, M. Barrera, R. Charco, J.Á. López-Baena, J. Briceño, F. Pardo, G. Blanco, D. Pacheco, B. Domínguez-Gil, V. Sánchez Turrión and C. Fondevila 658

Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation

N. Goldaracena, A. Gorgen, A. Doyle, B.E. Hansen, K. Tomiyama, W. Zhang, A. Ghanekar, L. Lilly, M. Cattral, Z. Galvin, M. Selzner, M. Bhat, N. Selzner, I. McGilvray, P.D. Greig, D.R. Grant and G. Sapisochin 666

### Cancer

The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention

Z. Liu, Y. Jiang, H. Yuan, Q. Fang, N. Cai, C. Suo, L. Jin, T. Zhang and X. Chen 674

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial

J.-W. Park, Y.J. Kim, D.Y. Kim, S.-H. Bae, S.W. Paik, Y.-J. Lee, H.Y. Kim, H.C. Lee, S.Y. Han, J.Y. Cheong, O.S. Kwon, J.E. Yeon, B.H. Kim and J. Hwang 684

Intraductal papillary neoplasm of the bile duct: Assessment of invasive carcinoma and long-term outcomes using MRI

S. Lee, M.-J. Kim, S. Kim, D. Choi, K.-T. Jang and Y.N. Park 692

Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma

M. Cadamuro, S. Brivio, J. Mertens, M. Vismara, A. Moncsek, C. Milani, C. Fingas, M. Cristina Malerba, G. Nardo, L. Dall'Olmo, E. Milani, V. Mariotti, T. Stecca, M. Massani, C. Spirli, R. Fiorotto, S. Indraccolo, M. Strazzabosco and L. Fabris 700

## Molecular and Cell Biology

### Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish

S. de Oliveira, R.A. Houseright, A.L. Graves, N. Golenberg, B.G. Korte, V. Miskolci and A. Huttenlocher 710

### Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis

H.-C. Tsay, Q. Yuan, A. Balakrishnan, M. Kaiser, S. Möbus, E. Kozdrowska, M. Farid, P.-K. Tegtmeyer, K. Borst, F.W.R. Vondran, U. Kalinke, A. Kispert, M.P. Manns, M. Ott and A.D. Sharma 722

## Genetic and Metabolic Diseases

### Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

M.E. Rinella, J.F. Trotter, M.F. Abdelmalek, A.H. Paredes, M.A. Connelly, M.J. Jaros, L. Ling, S.J. Rossi, A.M. DePaoli and S.A. Harrison 735

## REVIEWS

### Age and liver transplantation

F. Durand, J. Levitsky, F. Cauchy, H. Gilgenkrantz, O. Soubrane and C. Francoz 745

### Gap junctions in liver disease: Implications for pathogenesis and therapy

M. Hernández-Guerra, A. Hadjihambi and R. Jalan 759

## SPECIAL SECTIONS

## GRAND ROUNDS

### Grand round: Autoimmune hepatitis

P.J. Trivedi, S.G. Hubscher, M. Heneghan, D. Gleeson and G.M. Hirschfield 773

## Hepatology Snapshot

### The future of therapy for alcoholic hepatitis – Beyond corticosteroids

N. Vergis, S.R. Atkinson and M.R. Thursz 785

## LETTERS TO THE EDITOR

### HIV-positive to HIV-positive liver transplantation: To be continued

A. Lauterio, M.C. Moioli, S. Di Sandro, G. Travi, R. De Carlis, M. Merli, F. Ferla, M. Puoti and L. De Carlis 788

### It takes two “eyes” to see in depth

C. Ripoll, R. Bañares and A. Zipprich 790

### Reply to: “It takes two “eyes” to see in depth”

L. Turco, G. Garcia-Tsao, R. Rossi, E. Villa and F. Schepis 791

### Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors

G.P. Caviglia, F. Tandoi, A. Olivero, G.M. Saracco, M. Rizzetto, R. Romagnoli and A. Smedile 793

### Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues

J.-F. Tsai and D.-S. Perng 795

### Reply to: “Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues”

Y.-C. Hsu, T.C.-F. Yip, G.L.-H. Wong and C.-Y. Wu 796

### Influenza virus infection as precipitating event of acute-on-chronic liver failure

A. Schütte, S. Ciesek, H. Wedemeyer and C.M. Lange 797

### Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events

M. Tischendorf, A. Fuchs, S. Zeuzem and C.M. Lange 800

### Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF

A. Ferrarese, P. Feltracco, S. Barbieri, U. Cillo, P. Burra and M. Senzolo 801

### Reply to: “Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF”

S. van der Merwe, W. Laleman, L. Langouche and P. Meersseman 804

### Spleen in hepatocellular carcinoma: More complexity and importance than we knew

W. Wei, L. Li, G. Kong, Z. Zheng, F. Ji and Z. Li 805

### Liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection: A comment for moving forward

X. Xiang, Y. Wang, D.-C. Mo, S.-Q. Wang, X.-D. Xun, S.-H. Hu, Q. Cheng, Z. Li and J.-Y. Zhu 806

### Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade

T.-I. Huo, P.-H. Liu and C.-Y. Hsu 808

### Reply to correspondence concerning: “Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection”

G. Marasco, A. Colecchia, A. Colli, F. Ravaioli, G. Casazza, M.L. Bacchi Reggiani, A. Cucchetti, M. Cescon and D. Festi 809

### Midodrine and albumin in decompensated cirrhosis: Down but not out. . .

V. Singh, A. Singh and R. Agarwal 811

Reply to: “Midodrine and albumin in decompensated cirrhosis: Down but not out. . .”

E. Solà, C. Solé and P. Ginès

812

Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation

S.M. Kessler, J. Hoppstädter, K. Hosseini, S. Laggai, J. Haybaeck and A.K. Kiemer

813

Reply to: “Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation”

K. Borst, T. Graalman and U. Kalinke

815

## CORRIGENDUM

Corrigendum to “EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma” [J Hepatol 69 (2018) 182–236]

European Association for the Study of the Liver

817

---

## Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention, by Z. Liu et al. on pp. 674–683 in this issue.

Cover design: SEM image inspired illustration of liver cancer. Cover design by Caitlin Monney.